| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b12abe2b7dea2e664e82d068490559ed |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6923
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H13-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7028
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7024
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H15-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 |
| filingDate |
1995-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
1998-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-H10506372-A |
| titleOfInvention |
Use of βGalNac (1-4) βGal conjugate to treat Candida infection |
| abstract |
(57) [Summary]nDisclosed are methods for treating Candida albicans infection. In one embodiment, to treat an oral or vaginal infection, the treatment is by topical application of the conjugate composition. Each of the conjugates is composed of a carrier structure and a plurality of βGalNac (1-4) βGal moieties attached to the structure. In another embodiment, to treat a systemic infection, the treatment is by parenteral administration of a humanized form of a mouse monoclonal antibody produced by mouse hybridoma cell line Fm16 or cell line PK99H. |
| priorityDate |
1994-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |